eIF4E Phosphorylation in Prostate Cancer

Leandro S. D'Abronzo, Paramita M Ghosh

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Prostate cancer (PCa) progression involves a shift from endocrine to paracrine and eventually autocrine control resulting from alterations in molecular mechanisms in the cells. Deregulation of RNA translation is crucial for tumor cells to grow and proliferate; therefore, overactivation of the translation machinery is often observed in cancer. The two most important signal transduction pathways regulating PCa progression are PI3K/Akt/mTOR and Ras/MAPK. These two pathways converge on the eukaryotic translation initiation factor 4E (eIF4E) which binds to the protein scaffold eIF4G upon mechanistic target of rapamycin (mTOR) activation and is phosphorylated by the mitogen-activated protein kinase (MAPK) interacting protein kinases (Mnk1/2). This review describes the role of eIF4E in mRNA translation initiation mediated by its binding to the methylated 5′ terminal structure (m7G-cap) of many mRNAs, and the ability of many tumor cells to bypass this mechanism. Hormonal therapy and chemotherapy are two of the most prevalent therapies used in patients with advanced PCa, and studies have implicated a role for eIF4E phosphorylation in promoting resistance to both these therapies. It appears that eIF4E phosphorylation enhances the rate of translation of oncogene mRNAs to increase tumorigenicity.

Original languageEnglish (US)
Pages (from-to)563-573
Number of pages11
JournalNeoplasia (United States)
Volume20
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Eukaryotic Initiation Factor-4E
Eukaryotic Initiation Factors
Prostatic Neoplasms
Phosphorylation
Protein Biosynthesis
Sirolimus
Mitogen-Activated Protein Kinases
Neoplasms
Phosphatidylinositol 3-Kinases
Oncogenes
Protein Kinases
Signal Transduction
Therapeutics
RNA
Drug Therapy
Messenger RNA
Proteins

ASJC Scopus subject areas

  • Cancer Research

Cite this

eIF4E Phosphorylation in Prostate Cancer. / D'Abronzo, Leandro S.; Ghosh, Paramita M.

In: Neoplasia (United States), Vol. 20, No. 6, 01.06.2018, p. 563-573.

Research output: Contribution to journalReview article

D'Abronzo, Leandro S. ; Ghosh, Paramita M. / eIF4E Phosphorylation in Prostate Cancer. In: Neoplasia (United States). 2018 ; Vol. 20, No. 6. pp. 563-573.
@article{bb1fb3a6309f459ab23b16af5c3407ed,
title = "eIF4E Phosphorylation in Prostate Cancer",
abstract = "Prostate cancer (PCa) progression involves a shift from endocrine to paracrine and eventually autocrine control resulting from alterations in molecular mechanisms in the cells. Deregulation of RNA translation is crucial for tumor cells to grow and proliferate; therefore, overactivation of the translation machinery is often observed in cancer. The two most important signal transduction pathways regulating PCa progression are PI3K/Akt/mTOR and Ras/MAPK. These two pathways converge on the eukaryotic translation initiation factor 4E (eIF4E) which binds to the protein scaffold eIF4G upon mechanistic target of rapamycin (mTOR) activation and is phosphorylated by the mitogen-activated protein kinase (MAPK) interacting protein kinases (Mnk1/2). This review describes the role of eIF4E in mRNA translation initiation mediated by its binding to the methylated 5′ terminal structure (m7G-cap) of many mRNAs, and the ability of many tumor cells to bypass this mechanism. Hormonal therapy and chemotherapy are two of the most prevalent therapies used in patients with advanced PCa, and studies have implicated a role for eIF4E phosphorylation in promoting resistance to both these therapies. It appears that eIF4E phosphorylation enhances the rate of translation of oncogene mRNAs to increase tumorigenicity.",
author = "D'Abronzo, {Leandro S.} and Ghosh, {Paramita M}",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.neo.2018.04.003",
language = "English (US)",
volume = "20",
pages = "563--573",
journal = "Neoplasia (United States)",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - eIF4E Phosphorylation in Prostate Cancer

AU - D'Abronzo, Leandro S.

AU - Ghosh, Paramita M

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Prostate cancer (PCa) progression involves a shift from endocrine to paracrine and eventually autocrine control resulting from alterations in molecular mechanisms in the cells. Deregulation of RNA translation is crucial for tumor cells to grow and proliferate; therefore, overactivation of the translation machinery is often observed in cancer. The two most important signal transduction pathways regulating PCa progression are PI3K/Akt/mTOR and Ras/MAPK. These two pathways converge on the eukaryotic translation initiation factor 4E (eIF4E) which binds to the protein scaffold eIF4G upon mechanistic target of rapamycin (mTOR) activation and is phosphorylated by the mitogen-activated protein kinase (MAPK) interacting protein kinases (Mnk1/2). This review describes the role of eIF4E in mRNA translation initiation mediated by its binding to the methylated 5′ terminal structure (m7G-cap) of many mRNAs, and the ability of many tumor cells to bypass this mechanism. Hormonal therapy and chemotherapy are two of the most prevalent therapies used in patients with advanced PCa, and studies have implicated a role for eIF4E phosphorylation in promoting resistance to both these therapies. It appears that eIF4E phosphorylation enhances the rate of translation of oncogene mRNAs to increase tumorigenicity.

AB - Prostate cancer (PCa) progression involves a shift from endocrine to paracrine and eventually autocrine control resulting from alterations in molecular mechanisms in the cells. Deregulation of RNA translation is crucial for tumor cells to grow and proliferate; therefore, overactivation of the translation machinery is often observed in cancer. The two most important signal transduction pathways regulating PCa progression are PI3K/Akt/mTOR and Ras/MAPK. These two pathways converge on the eukaryotic translation initiation factor 4E (eIF4E) which binds to the protein scaffold eIF4G upon mechanistic target of rapamycin (mTOR) activation and is phosphorylated by the mitogen-activated protein kinase (MAPK) interacting protein kinases (Mnk1/2). This review describes the role of eIF4E in mRNA translation initiation mediated by its binding to the methylated 5′ terminal structure (m7G-cap) of many mRNAs, and the ability of many tumor cells to bypass this mechanism. Hormonal therapy and chemotherapy are two of the most prevalent therapies used in patients with advanced PCa, and studies have implicated a role for eIF4E phosphorylation in promoting resistance to both these therapies. It appears that eIF4E phosphorylation enhances the rate of translation of oncogene mRNAs to increase tumorigenicity.

UR - http://www.scopus.com/inward/record.url?scp=85046796085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046796085&partnerID=8YFLogxK

U2 - 10.1016/j.neo.2018.04.003

DO - 10.1016/j.neo.2018.04.003

M3 - Review article

C2 - 29730477

AN - SCOPUS:85046796085

VL - 20

SP - 563

EP - 573

JO - Neoplasia (United States)

JF - Neoplasia (United States)

SN - 1522-8002

IS - 6

ER -